Results 131 to 140 of about 3,186 (208)

[Adverse reactions to drugs used for COVID-19 in five Latin American countriesReações adversas a medicamentos utilizados para a COVID-19 em cinco países da América Latina]. [PDF]

Rev Panam Salud Publica, 2022
Orjuela-Rodríguez T, Rojas-Cortés R, Vergara V, Aldunate F, Jiménez G, Orta IA, Serrano K, Jiménez G, Gil González DM, Gutiérrez D, Cortez FB, González JD, Porrás A, Castro JL.   +13 more
europepmc   +1 more source

Bol CIM 220 : Informes de farmacovigilancia

, 2015
Fil: Fil: Centro de Información de Medicamentos (CIM). Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Área de Farmacia Asistencial; Argentina.
openaire   +1 more source

Signals of disproportionate reporting of events supposedly attributable to COVID-19 vaccines in children and adolescents: case-non-case study, Brazil, 2022. [PDF]

Epidemiol Serv Saude
Silva RMA, Nóbrega MEBD, Percio J, Martins AF, Almeida SLR, Porto VBG.   +5 more
europepmc   +1 more source

[Medication Review with Follow-up Service provided by the Community Pharmacy as a care practice for the optimization of pharmacotherapy in patient with urticaria and pruritus]. [PDF]

Farm Comunitarios, 2023
Pérez Rodríguez RO, Barreto Corujo NJ.
europepmc   +1 more source

Boletín de farmacovigilancia y tecnovigilancia, junio 2020

, 2020
En esta edición presentamos el análisis de la base de datos de notificaciones de sospechas de incidentes adversos a dispositivos médicos enviadas por las empresas titulares del registro sanitario o titulares de certificado de registro sanitario y de profesionales de la salud, correspondientes al año 2019; los resultados de la evaluación de los ...
openaire   +1 more source

[Initial clinical experience with ribociclib in advanced HR+/HER2- breast cancer in Uruguay]. [PDF]

Rev Med Inst Mex Seguro Soc
Camejo-Martínez N, Strazzarino-Peluffo N, Amarillo-Hernández C D, Castillo-Leska C, Krygier-Waltier G.   +4 more
europepmc   +1 more source

Medicines withdrawn in other countries due to safety problems, between 2014 and 2023, and their permanence in the Argentine market. [PDF]

Rev Fac Cien Med Univ Nac Cordoba
Caffaratti M, Cañás M, Domosbian DE, Giraudo E, González AM, Lorenzo A, Núñez Montoya S, Rocha MT, Traverso ML, Uema S.   +9 more
europepmc   +1 more source

[Strategies and Barriers to the Implementation of Continuing Education in Sentinel Hospitals for the Surveillance of COVID-19 Vaccine Safety in Honduras, 2022-2023Formação continuada: estratégias e barreiras de implementação em hospitais sentinela para a vigilância da segurança das vacinas contra a COVID-19 em Honduras, 2022-2023]. [PDF]

Rev Panam Salud Publica
Zúniga C, Cárcamo E, Romualdo-Tello NM, Solarte Agredo IN, Álvarez V, Moya I, Galeas J, Burgos N, Raudales A, Zapata L, Soto S, Gamero M.   +11 more
europepmc   +1 more source

[Bullous pemphigoid associated with dipeptidil peptidase-4 inhibitors]. [PDF]

Aten Primaria, 2023
Garriga Casanovas A.
europepmc   +1 more source

Patterns and persistence of use, effectiveness, safety, clinical inertia, and adherence related to Levothyroxine treatment with real-world evidence. An observational, longitudinal and retrospective study. [PDF]

Endocrine
Valladales-Restrepo LF, Londoño-Cano DA, Muñoz-Velez CM, Soto-Romero LM, Tafur-Ramirez ME, Rojas-Varón MJ, Machado-Alba JE.   +6 more
europepmc   +1 more source